Barinthus Biotherapeutics plc (NASDAQ:BRNS) Sees Significant Increase in Short Interest

Barinthus Biotherapeutics plc (NASDAQ:BRNS) was the target of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 14,800 shares, an increase of 31.0% from the February 28th total of 11,300 shares. Based on an average daily trading volume, of 34,700 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company’s shares are short sold.

Institutional Investors Weigh In On Barinthus Biotherapeutics

A hedge fund recently bought a new stake in Barinthus Biotherapeutics stock. Gilead Sciences Inc. purchased a new stake in Barinthus Biotherapeutics plc (NASDAQ:BRNS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 620,351 shares of the company’s stock, valued at approximately $749,000. Barinthus Biotherapeutics accounts for approximately 0.0% of Gilead Sciences Inc.’s holdings, making the stock its 14th largest holding. Gilead Sciences Inc. owned approximately 1.54% of Barinthus Biotherapeutics as of its most recent SEC filing. 25.20% of the stock is currently owned by institutional investors.

Barinthus Biotherapeutics Price Performance

Shares of BRNS stock opened at $0.80 on Wednesday. Barinthus Biotherapeutics has a 1-year low of $0.79 and a 1-year high of $4.16. The firm has a market cap of $32.37 million, a PE ratio of -0.54 and a beta of -0.80. The company has a 50-day moving average of $1.01 and a two-hundred day moving average of $1.10.

Barinthus Biotherapeutics (NASDAQ:BRNS) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). The company had revenue of $14.97 million for the quarter. Sell-side analysts anticipate that Barinthus Biotherapeutics will post -1.38 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and set a $3.00 price target on shares of Barinthus Biotherapeutics in a research report on Friday, March 21st.

Barinthus Biotherapeutics Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer.